Recent clinical and preclinical evidence suggests that psychedelics and entactogens may
produce both rapid and sustained therapeutic effects across several indications. Currently …

Psychedelics, also known as classical hallucinogens, have been investigated for decades
due to their potential therapeutic effects in the treatment of neuropsychiatric and substance …

We examined if the therapeutic alliance between study participants and intervention
facilitators in a psilocybin-assisted therapy (PAT) trial changed over time and whether there …

Objective: Despite considerable research examining the efficacy of psychedelic-assisted
therapies (PATs) for treating psychiatric disorders, assessment of adverse events (AEs) in …

Cannabis and classic psychedelics are controlled substances with emerging evidence of
efficacy in the treatment of a variety of psychiatric illnesses. Cannabis has largely not been …

Introduction Psychedelic-assisted therapy with psilocybin has shown promise in Phase 2
trials for alcohol use disorder (AUD). Set and setting, particularly factors facilitating a …

Recent research with classic psychedelics suggests significant therapeutic potential,
particularly for neuropsychiatric disorders. A mediating influence behind symptom resolution …

In contrast to well established psychedelics such as lysergic acid diethylamide (LSD) and
psilocybin, ergot alkaloids of the clavine subclass have not been thoroughly investigated, in …

This narrative review explores the utilization of psychedelic states in therapeutic contexts,
deliberately shifting the focus from psychedelic substances back to the experiential …

There has been a burgeoning interest in psychedelics among the public, state legislatures,
psychiatrists and other clinical providers, and within the research community. Increasing …